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M-Ras is a Ras-related protein that shares ;55% iden-
tity with K-Ras and TC21. The M-Ras message was
widely expressed but was most predominant in ovary
and brain. Similarly to Ha-Ras, expression of mutation-
ally activated M-Ras in NIH 3T3 mouse fibroblasts or C2
myoblasts resulted in cellular transformation or inhibi-
tion of differentiation, respectively. M-Ras only weakly
activated extracellular signal-regulated kinase 2
(ERK2), but it cooperated with Raf, Rac, and Rho to
induce transforming foci in NIH 3T3 cells, suggesting
that M-Ras signaled via alternate pathways to these ef-
fectors. Although the mitogen-activated protein kinase/
ERK kinase inhibitor, PD98059, blocked M-Ras-induced
transformation, M-Ras was more effective than an acti-
vated mitogen-activated protein kinase/ERK kinase mu-
tant at inducing focus formation. These data indicate
that multiple pathways must contribute to M-Ras-in-
duced transformation. M-Ras interacted poorly in a
yeast two-hybrid assay with multiple Ras effectors, in-
cluding c-Raf-1, A-Raf, B-Raf, phosphoinositol-3 kinase
d, RalGDS, and Rin1. Although M-Ras coimmunoprecipi-
tated with AF6, a putative regulator of cell junction
formation, overexpression of AF6 did not contribute to
fibroblast transformation, suggesting the possibility of
novel effector proteins. The M-Ras GTP/GDP cycle was
sensitive to the Ras GEFs, Sos1, and GRF1 and to p120 Ras
GAP. Together, these findings suggest that while M-Ras is
regulated by similar upstream stimuli to Ha-Ras, novel
targets may be responsible for its effects on cellular trans-
formation and differentiation.
The mammalian Ras superfamily is made up of over 60
GTPases that serve as molecular switches to regulate a diverse
array of cellular functions. These include intracellular signal
transduction for cell growth and differentiation (Ras subfami-
ly), regulation of the actin cytoskeleton (Rho subfamily), mem-
brane trafficking (Rab subfamily), and nuclear transport (Ran)
(1–4). The Ras subfamily consists of Ha-, Ki-, and N-Ras;
Krev-1/Rap1A and -1B; Rap2A and -2B; R-Ras; TC21(R-Ras2);
Ral A and B; Rheb; Dex-Ras; Rin; and Rit that share several
common features outside of the core GTP-binding domain (2).
The classic/prototypic Ras proteins, Ha-, Ki-, and N-Ras, trans-
duce signals for growth and differentiation from ligand-bound
receptors to the nuclear transcriptional machinery and to the
cytoskeleton (2, 3, 5, 6). These proteins can be constitutively
activated by point mutation, contributing to the development of
a broad spectrum of human malignancies (7). The introduction
of equivalent activating mutations into the closely related
TC21 and R-Ras proteins also results in transformation in
tissue culture models (8, 9), and TC21 mutants have been
identified in human tumor cell lines (10, 11). R-Ras has also
been associated with apoptosis and integrin activation (12, 13).
Overexpression of Rap1A/Krev-1 can induce transformation in
some cells (14) but typically has been found to counter Ras-
induced activities, due to competitive binding to Ras effectors
(15, 16). Rheb similarly can inhibit Ras-induced transformation
(17), but both the Rap and Rheb proteins may have other
physiological functions; e.g. Rap1A contributes to the differen-
tiation of PC12 cells into neurites via activation of B-Raf and
has been linked to superoxide generation in phagocytes (18,
19). Ral acts downstream from Ras proteins in a signaling
cascade that regulates the activity of phospholipase D (20).
Each of the above Ras-related proteins operates as a molec-
ular switch that cycles between inactive GDP- and active GTP-
bound states. This cycle is tightly controlled in vivo by two
classes of regulatory proteins. Guanine nucleotide exchange
factors (GEFs)1 promote the release of GDP from inactive Ras
and stabilize the apoprotein so that it can acquire the active,
GTP-bound state (5). GTPase-activating proteins (GAPs)
meanwhile promote rapid hydrolysis of Ras-GTP back to the
inactive GDP-bound state (21), thus completing the cycle. On-
cogenic mutations block GAP-stimulated GTPase activity, thus
causing Ras to be locked in the active, GTP-bound, conforma-
tion. The various Ras proteins have both specific and overlap-
ping sensitivities to GEFs and GAPs; e.g. the Ras GEF Sos1 can
activate Ha-Ras and TC21 but not R-Ras or Rap1A (22, 23), while
C3G can activate Rap1A and R-Ras but not Ha-Ras (23). Follow-
ing acquisition of the active GTP-bound state, Ras can interact
with a variety of cellular targets to elicit its biological effects.
These include the Raf Ser/Thr protein kinases that activate the
ERK cascade, phosphatidylinositol 3 kinase (PI3K) and the Ral
exchange factors, RalGDS, Rgl, and Rgl2/Rlf (2). Additional Ras-
interacting proteins (e.g. Rin1, AF6, and NORE) have been iden-
tified that may also serve as downstream effectors (24–27).
A search of the NCBI expressed sequence tag data base for
Ras-related gene products revealed a novel cDNA that, upon
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complete sequencing, was found to share 55% amino acid iden-
tity with TC21 and Ki-Ras4B. This protein has since been
independently described as M-Ras (28) and R-Ras3 (29). Fol-
lowing the introduction of an activating mutation equivalent to
that known to potently enhance the oncogenic activity of Ha-
Ras (30), overexpression of M-Ras(Q71L) caused morphologic
and growth transformation in a manner similar to but distinct
from Ha-Ras(Q61L). Similarly to Ha-Ras, overexpression of
mutationally activated M-Ras also inhibited the differentiation
of C2 myoblasts into myotubes. The ability of M-Ras to induce
transcriptional activation and transformation was blocked by
the MEK inhibitor PD98059, suggesting the importance of
ERK activation to its biological activity. However, M-Ras was
considerably more effective than an activated MEK mutant
(MEKDED) at inducing NIH 3T3 cellular transformation, de-
spite being a weaker activator of Elk-1. This suggested that
multiple downstream targets contribute to M-Ras-induced
transformation. However, M-Ras did not interact with Ras
effectors in a yeast two-hybrid interaction assay. Although
M-Ras did interact strongly with AF6, a putative downstream
target of the Ha-Ras protein (24, 25), AF6 overexpression did
not contribute to fibroblast transformation. M-Ras was acti-
vated by the Ras-specific GEF, Sos1, and its GTPase activity
was sensitive to p120 Ras GAP, suggesting that M-Ras can be
regulated by similar upstream pathways to Ha-Ras. However,
since M-Ras demonstrated differential Ras effector interactions
as well as differential tissue distribution compared with Ha-, Ki-,
or N-Ras, it may serve a unique physiological function.
EXPERIMENTAL PROCEDURES
cDNA Manipulation—Clone AA035915 (Genome Systems Inc.) was
found to encode a full-length mouse M-ras cDNA. 59 BamHI and 39
BamHI and EcoRI sites were introduced by polymerase chain reaction-
mediated DNA amplification. An activating Q71L mutation was also
introduced by two-step polymerase chain reaction, and all products
were sequenced prior to subcloning into the pZIP-NeoSV(X)1 (31),
pCGN (32), or pGEX 2T (Amersham Pharmacia Biotech) expression
vectors. Codons 4–1613 of the AF6 cDNA (provided by M. White,
University of Texas Southwestern Medical Center) were subcloned as
an EagI fragment into the pFLAG-CMV2 vector (Eastman Kodak Co.)
after frameshifting the polylinker by filling in and blunt-ligating the
HindIII site. The pZIP-Ha-ras(Q61L), pcDNA3-cSos-CAAX (33),
pRCbac-(59-SosF) (34), pDCR-Ha-ras(G12V) (35) and pMLC-MEKDED
(36) plasmids have previously been described.
Northern Blot—An ;1,100-base pair fragment encoding the M-ras
cDNA was radiolabeled using [a-32P]dCTP and a random-primed DNA-
labeling kit (Roche Molecular Biochemicals) and used to screen a mouse
RNA Master Blot (CLONTECH), essentially as described by the man-
ufacturers. Hybridization was detected by overnight autoradiography
at 280 °C, using an intensifying screen.
NIH 3T3 Cell Culture, Transformation, and Transcription Assays—
NIH 3T3 mouse fibroblasts were cultured in Dulbecco’s modified Ea-
gle’s medium supplemented with 10% donor calf serum (Life Technol-
ogies, Inc.) and transfected essentially as described (37). Transforming
focus forming assays and soft agar assays were performed in NIH 3T3
cells as previously outlined (37, 38). The appearance of foci was scored
16 days post-transfection. For transcriptional activation assays, NIH
3T3 cells were transfected with 0.75 mg of pZIP-ras together with 125 ng
of Gal4-Elk and 2.5 mg of 5XGal4-Luc reporter plasmids (39) plus the
indicated co-stimuli. 24 h post-transfection, cells were starved (0.5%
serum), and luciferase activity was assayed the following day essen-
tially as described (40).
C2 Cell Culture and Differentiation—C2 myoblast cells (provided by
Y. Xhong) were grown in Dulbecco’s modified Eagle’s medium supple-
mented with 15% fetal bovine serum. One mg of pZIP plasmid encoding
WT or activated M-Ras(Q71L) or Ha-Ras(Q61L) proteins were transfected
into C2 cells using calcium phosphate precipitation. After 24 h, cells were
selected in growth medium supplemented with 400 mg/ml G418 to estab-
lish mass populations of cells expressing the indicated Ras proteins. To
induce differentiation, C2 cells were grown to 70% confluence and then fed
with Dulbecco’s modified Eagle’s medium containing 2% horse serum and
10 mg/ml insulin (Life Technologies). After approximately 7 days, cells
were scored for acquisition of differentiated characteristics.
Mitogen-activated Protein Kinase Assay—NIH 3T3 cells were co-
transfected with 1 mg of pcDNA3-HA-ERK2 (encoding hemagglutinin
(HA) epitope-tagged ERK2) plus 2 mg of pcDNA3 alone or encoding
Ha-Ras(Q61L) or M-Ras(Q71L) using LipofectAMINE (Life Technolo-
gies). After 24 h, cells were serum-starved (0.1%) overnight and lysed in
20 mM Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM EGTA, 0.27 M sucrose, 0.1%
SDS, 1% Triton X-100, 0.5% deoxycholate, 1 mM Na3VO4 50 mM NaF,
0.1% b-mercaptoethanol, 10 mM b-glycerophosphate, 19 mg/ml aproti-
nin, and 1 mM phenylmethylsulfonyl fluoride. HA-ERK2 was immuno-
precipitated using anti-HA monoclonal antibody (Babco) and ERK ki-
nase activity was determined using myelin basic protein (Sigma) as
substrate, essentially as described (41). c-Jun N-terminal kinase assays
were performed similarly following cotransfection of NIH 3T3 cells with
pCMV-FLAG-JNK and using glutathione S-transferase-Jun-(1–79) as
substrate. To determine p38 activation levels, NIH 3T3 cells were
transfected with FLAG-tagged p38a. Cells were serum-starved as above
prior to lysis and Western blotting with an anti-activated p38 antibody
(New England Biolabs). Equal loading of lanes was confirmed by blot-
ting for FLAG-tagged p38 with M2 anti-FLAG antibody. Treatment
with 10 mg/ml anisomycin (Calbiochem) for 10 min was used as a
positive control for c-Jun N-terminal kinase or p38 activation. ERK
activity in stable cell lines was determined using an anti-activated ERK
polyclonal antiserum (Promega).
Yeast Two-hybrid Protein-Protein Interaction—The system used was
a modification of the Fields’ two-hybrid system, where one hybrid is
fused between the LexA DNA binding domain (amino acids 1–211) and
the Ha-Ras(G12V) or M-Ras(Q71L) protein. The second hybrid is a
fusion between a nuclear localized VP16 acidic activation domain and
full-length RalGDS, cRaf-1, A-Raf, B-Raf, or PI3K p110d (provided by A.
Vojtek), truncated AF6 (provided by L. van Aelst), Rin1 (provided by J.
Colicelli), or c-Raf-1. Individually, these hybrids did not activate tran-
scription. However, when co-expressed in a Saccharomyces cerevisiae
strain that contains two integrated reporter constructs (yeast HIS3 and
the bacterial lacZ gene), the yeast strain expressing both hybrid pro-
teins that are capable of forming interactions is prototrophic for histi-
dine and contains detectable b-galactosidase activity (42). For b-galac-
tosidase expression assays, yeasts co-expressing the indicated Ras and
Ras effector plasmids were grown overnight in 5 ml of SC medium
without Trp or Leu. Approximately 107 cells (based on A600) were
resuspended in 1 ml of Z buffer, lysed by the addition of two drops of
10% SDS and three drops of chloroform, and cleared by microcentrifu-
gation. Lysates were spiked with 200 ml of o-nitrophenyl b-D-galacto-
pyranoside (4 mg/ml) and incubated at 28 °C until color developed.
b-Galactosidase activity was expressed as A420 3 1000/(A600 3 time).
Coprecipitation of AF6 and Ras Proteins—Human embryonic kidney,
293T, cells were plated at 8 3 105 cells/90-mm dish and transfected the
following day with pFLAG-CMV2-AF6 (encoding FLAG epitope-tagged
AF6) and pCGN, pCGN-M-ras(Q71L), or pDCR-Ha-ras(G12V) using
LipofectAMINE (Life Technologies) or calcium phosphate precipitation
as described (37). Both Ras proteins were HA epitope-tagged. 48 h later,
cells were washed with ice-cold phosphate-buffered saline and lysed in
50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.1 mM MgCl2, 0.5% Nonidet
P-40, 10% glycerol, 19 mg/ml aprotinin, and 1 mM phenylmethylsulfonyl
fluoride. After centrifugation (refrigerated microcentrifuge, 10 min),
the supernatant was precleared by incubation with protein A/G-agarose
beads (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) for 10 min. The
supernatant was then tumbled with 5 mg of anti-HA antibody (Babco)
and 30 ml of protein A/G-agarose beads for 60 min and washed four times
with lysis buffer, and proteins were separated by SDS-polyacrylamide gel
electrophoresis (7% gel). Following transfer to polyvinylidene difluoride
membrane (Millipore Corp.), co-precipitated AF6 was detected using M2
anti-FLAG antibody (Sigma), horseradish peroxidase-conjugated second
antibody and ECL reagents (Amersham Pharmacia Biotech).
GEF and GAP Assays—In vivo guanine nucleotide exchange assays
were performed essentially as described (23). Briefly, 293T cells were
transiently transfected with plasmids encoding the indicated Ras and
GEF proteins. After 36 h, cells were incubated in serum and phosphate-
free medium for 30 min followed by similar medium supplemented with
150 mCi of 32Pi for an additional 4 h. Cells were washed with ice-cold
phosphate-buffered saline, lysed in 50 mM Tris-HCl, pH 7.4, 50 mM
NaCl, 6 mM MgCl2, 1 mM EDTA, 1% Triton X-100, 0.5% sodium deoxy-
cholate, 0.05% SDS, 19 mg/ml aprotinin, and 1 mM phenylmethylsulfo-
nyl fluoride, and clarified by microcentrifugation for 10 min, and Ras
proteins were immunoprecipitated using anti-HA or FLAG antibody.
Ras proteins were then denatured at 68 °C in 0.2% SDS, 2 mM EDTA,
and guanine nucleotides were separated by thin layer chromatography
on polyethyleneimine-cellulose plates using 0.75 M KH2PO4/HCl, pH
3.4, as solvent. Chromatograms were dried and quantified using an
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AMBIS b-scanner. To measure GAP activity, glutathione S-transferase-
M-Ras and Ha-Ras fusion proteins were expressed in Escherichia coli
and bound to glutathione-agarose beads in the presence of 50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM GDP, 1 mM MgCl2, 1% Triton
X-100, 1 mM dithiothreitol, 19 mg/ml aprotinin, and 1 mM phenylmeth-
ylsulfonyl fluoride. Bead-bound proteins were loaded with GTP by in-
cubation, 10 min at 30 °C, in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5
mM EDTA, 1 mg/ml bovine serum albumin, 6 mM GTP, 5 mCi of
[g-32P]GTP, 1 mM dithiothreitol. MgCl2 was added to 10 mM, and free
nucleotide was removed by washing beads three times with the loading
buffer minus GTP. Proteins were then eluted by incubating beads with
100 ml of 100 mM Tris-HCl, pH 8.0, 10 mM MgCl2 and 20 mM glutathione
on ice for 20 min. 0.2 pmol of GTP-bound Ras (determined by scintilla-
tion counting) was then incubated for the indicated times with or
without 5 ng of p120 Ras GAP (provided by G. Bollag, ONYX Pharma-
ceuticals) in a 50-ml final reaction volume containing 25 mM Tris-HCl,
1.5 mg/ml bovine serum albumin, 7.5 mM MgCl2, 2 mM dithiothreitol at
room temperature for the indicated times. The reaction was stopped by
the addition of 4 ml of 0.5 M EDTA and 1 ml of 10% SDS and heating to
68 °C for 5 min. Guanine nucleotides were separated as above.
RESULTS
M-Ras Is Closely Related to Ras and Has a Broad Tissue
Distribution—A search of the NCBI expressed sequence tag
data base revealed, in addition to multiple copies of known ras
superfamily sequences, a unique cDNA present in both mouse
and human libraries. Sequencing of clone AA035915 revealed
an open reading frame of 208 codons that shared ;55% identity
with Ki-Ras4B and TC21. This cDNA will be referred to here as
M-ras in accordance with Matsumoto et al. who recently iso-
lated this sequence from the murine myoblast C2 cell line (28).
M-Ras shares many features characteristic of the Ras subfam-
ily of GTPases (see Refs. 28 and 29). In particular, it shares
complete identity with the core effector-binding domain se-
quence of Ha-, Ki-, and N-Ras (residues 32–40; Fig. 1).
To address the tissue distribution of M-Ras, an [a–32P]dCTP-
labeled cDNA probe was generated and used to screen a mouse
RNA Master Blot (CLONTECH). As shown in Fig. 2, the M-Ras
message was most highly expressed in ovary and brain with
lower level detection in many additional tissues including
uterus, kidney, spleen, prostate, and lung. A constant level of
M-Ras message was also detectable at various stages of devel-
opment in the whole embryo, possibly reflecting transcription
in brain. Although the M-ras message is widely expressed, it
exhibits a different distribution pattern from that of Ha-ras
(which is most abundant in skin, brain, and skeletal muscle),
Ki-ras (most prevalent in gut, lung, and thymus), or N-ras
(most abundant in thymus and testis) (43).
M-Ras Induces Cellular Transformation—To establish
whether M-Ras harbors transforming ability similar to the
related Ras, TC21, and R-Ras proteins, we introduced an acti-
vating mutation, Q71L, equivalent to that found in the highly
transforming Ha-Ras(Q61L) (30). As seen in Fig. 3A, M-Ras-
(Q71L) had approximately 10% of the transforming potential of
Ha-Ras(Q61L), generating 563 6 29 compared with 4975 6 296
foci/mg (mean 6 S.E. for three experiments performed in quad-
ruplicate) in NIH 3T3 cell focus forming assays. As seen in Fig.
3B, M-Ras-transformed foci were typically smaller than those
induced by Ha-Ras, and the transformed cells were subtly
different from those transformed by activated Ha-Ras and
TC21,2 being less refractile and producing more elongated ex-
tensions at the periphery. This morphology was also quite
distinguishable from the dense, nonrefractile foci induced by
R-Ras (9). Individual colonies were isolated from NIH 3T3 cells
that had been transfected with pZIP-Ha-ras(Q61L), pZIP-M-
ras(Q71L), or empty vector and stably selected on G418. These
cells were then cultured in soft agar to assess anchorage-inde-
pendent growth. Fig. 3C shows that M-Ras-transformed cells
can grow in soft agar similarly to Ha-Ras-transformed cells,
although the colonies from M-Ras-expressing cells were typi-
cally smaller. Like Ras-transformed cells, M-Ras-transformed
cells could also survive and grow in low serum (0.5%).2
M-Ras Suppresses the Differentiation of C2 Myoblasts—M-
Ras was so named due to its isolation from a C2 myoblast cDNA
library. Further, it was found that the M-Ras message level
decreased upon differentiation of C2 cells into myofibers (28).
This suggested that M-Ras might be responsible for restraining
cellular differentiation. The differentiation of cultured myo-
blasts into myotubes is normally kept in check by the inhibitory
effects of serum mitogens on the transcriptional activity of
muscle regulatory factors such as MyoD. However, upon serum
deprivation, cells differentiate and then fuse to form myotubes.
Oncogenic Ras can inhibit this process and, in the presence of
serum, can induce myoblast transformation (44). As shown in
Fig. 4, while C2 myoblasts expressing wild type M-Ras still
differentiated and fused into myotubes upon fetal bovine serum
withdrawal, cells overexpressing activated Ha- or M-Ras did
not. Both Ha-Ras(Q61L) and M-Ras(Q71L) caused morpholog-
ical transformation of C2 cells in the presence of serum.3
M-Ras Weakly Activates ERK2—Since M-Ras could induce
similar biological effects to Ha-Ras, we next wished to address
whether this was due to M-Ras activating the same down-
stream effectors utilized by Ha-Ras. Ras family GTPases can
induce the activation of several mitogen-activated protein ki-
nase cascades. Therefore, we compared the ability of Ha- and
M-Ras to activate the ERK, c-Jun N-terminal kinase, and p38
mitogen-activated protein kinases. As shown in Fig. 5A, follow-
ing transient coexpression of M-Ras or Ha-Ras with HA-tagged
ERK2 in NIH 3T3 cells, the kinase activity of immunoprecipi-
tated ERK2 was only moderately elevated (;2-fold) by M-Ras-
(Q71L) compared with a 50-fold elevation by Ha-Ras(Q61L).
Although TC21 did not induce ERK activation following tran-
sient transfection (8), stably transformed cells possess elevated
ERK activity. Therefore, we used an anti-activated ERK anti-
body that only recognizes ERKs that have been doubly phos-
phorylated on Thr and Tyr to assess the activation state of
ERKs in stably transformed cells. As shown in Fig. 5B, while
there was considerably more ERK activation in Ha-Ras(Q61L)-
transformed cells, there was a modest elevation of active, phos-
phorylated, ERKs in M-Ras-expressing versus control cells that
may contribute to their transformed state. There was little
detectable c-Jun N-terminal kinase activation by Ha- or M-Ras,
as determined by an immunocomplex kinase assay using glu-
tathione S-transferase-Jun-(1–79) as substrate.2 Similarly, fol-
lowing co-transfection of NIH 3T3 cells with activated Ha- or
2 L. A. Quilliam, A. F. Castro, and C. Bi, unpublished observation.
3 C. B. Martin and C. J. Der, unpublished observation.
FIG. 1. Alignment of the effector-binding domains of Ras fam-
ily GTPases. Residues 30–58 of M-Ras were aligned with residues
20–48 of Ha-Ras, Ki-Ras, and Rap1 and the equivalent residues of
TC21 (residues 31–59), R-Ras (residues 46–74), RalA (residues 31–59),
Rit (residues 38–66), and Rheb (residues 23–51) using ClustalW. Ha-
Ras residues are indicated. Black and gray shading (generated using
MacBoxshade) indicates sequence identity and homology, respectively.
The switch 1 domain Ha-Ras residues 32–38 are underlined.
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M-Ras plasmids and FLAG epitope-tagged p38, neither
GTPase was found to significantly stimulate p38 activity, as
determined by anti-active p38 antibody blotting (Fig. 5C).
M-Ras-induced Elk-1 Activation and Cellular Transforma-
tion Require the MEK/ERK Pathway—Ha-Ras can induce gene
expression via the transcription factor Elk-1, which lies down-
stream of the Raf/ERK cascade. Similarly, M-Ras(Q71L) in-
duced Elk-driven luciferase expression but, as in the transfor-
mation studies, was less potent than Ha-Ras(Q61L) (Fig. 6A).
To establish whether activation of Elk-1 by M-Ras was due, at
least in part, to the modest elevation of ERK activity reported
above, we incubated cells with the MEK inhibitor PD98059 for
16 h prior to harvesting. Elk-1 has also been reported to be
sensitive to p38 activation in some cell types (reviewed in Ref.
45). Therefore, we also pretreated cells with the p38 inhibitor
SB203580. As shown in Fig. 6A, PD98059 almost completely
blocked the ability of M-Ras or activated MEK to induce lucif-
erase activity in the Gal-Elk reporter assay, suggesting that
the MEK/ERK pathway was probably the sole upstream medi-
ator of Elk-1 phosphorylation. In contrast, SB203580 modestly
stimulated M-Ras-induced luciferase activity, suggesting that
p38 could negatively regulate Elk-1 activation.
To determine whether the MEK/ERK pathway was also es-
sential for M-Ras-induced transformation, NIH 3T3 focus form-
ing assays were performed in the presence of 50 mM PD98059 or
10 mM SB203580. While the MEK inhibitor had only a modest
effect on the focus forming ability of Ha-Ras(Q61L), it com-
pletely blocked M-Ras(Q71L)-induced transformation (Fig. 6B).
At a concentration of 10 mM PD98059 or using another MEK
inhibitor, U0126 (46), there was still a loss (U0126) or consid-
erable reduction (10 mM PD98059) of M-Ras-induced foci, but
only the morphology of Ha-Ras-transformed cells was altered.2
In contrast, the presence of SB203580 potentiated M-Ras-in-
duced transformation. These findings suggested that M-Ras
was acting via MEK to induce transformation. However, since
the strongly activating MEKDED mutant that potently stimu-
lated Elk-1 activation did not induce focus formation (Fig. 6C),
it seemed likely that M-Ras must also signal via pathways in
addition to Raf/MEK/ERKs to invoke its biological effects.
M-Ras Cooperates with Raf, Rho, and Rac to Induce NIH 3T3
Cell Transformation—Co-transfection of NIH 3T3 cells with
two or more Ha-Ras effectors (e.g. Rho plus Raf or Raf plus
RalGDS) results in their cooperation to induce Ras-like foci (47,
48). Therefore, we speculated that M-Ras might synergize with
FIG. 2. The M-Ras message is widely
expressed. A mouse mRNA Master Blot
(CLONTECH) was hybridized with a 32P-
labeled probe generated from the 1.1-ki-
lobase pair mouse M-Ras cDNA.
FIG. 3. M-Ras induces morphologic transformation of NIH 3T3
cells. A, NIH 3T3 cells transfected with plasmids encoding the indi-
cated proteins were grown in regular culture medium for 12–18 days
prior to staining with crystal violet. Data are representative of four
experiments performed in quadruplicate. B, individual foci from A were
photographed at 3 4 magnification. C, NIH 3T3 cells stably expressing
the indicated Ras proteins were grown in soft agar for 2 weeks prior to
photographing colonies at 3 4 magnification.
FIG. 4. Activated M-Ras attenuated the fusion of C2 myoblasts.
C2 myoblasts were transfected with pZIP plasmid constructs encoding
the indicated Ras proteins. Following stable selection on G418, .50
colonies were pooled and replated. Cells were shifted from growth
medium containing 15% FBS to 2% horse serum, 10 mg/ml insulin to
induce muscle differentiation. The left panel shows that, similarly to
control cells, cells expressing wild type M-Ras differentiate and fuse to
form myotubes. In contrast, cells expressing mutationally activated
M-Ras(Q71L) or Ha-Ras(Q61L) fail to form myotubes. Instead, these
cells became transformed and overcame density arrest. Results show
representative fields from several independent experiments.
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Ha-Ras effectors not already efficiently activated by M-Ras. As
shown in Fig. 7A, M-Ras cooperated with activated mutants of
Raf, Rho, and Rac to induce transforming foci, suggesting that
it signaled via alternative effector proteins.
M-Ras Interacts with AF6 but Not with Other Putative Ras
Effectors—The data described above suggested that M-Ras re-
lied on a downstream target(s) in addition to ERKs to induce
morphologic transformation. Since Ras signals via multiple
effectors to elicit its biological responses, it was possible that
Ha-Ras targets also contributed to M-Ras-induced transforma-
tion. Alternatively, since M-Ras diverges from Ras in se-
quences flanking the core effector-binding region (spanning
residues 35–40 and 50–55; Fig. 1), and these flanking se-
quences are important for Ras effector binding (2), it was pos-
sible that M-Ras might have only limited interaction with
known Ras effectors. To determine which Ras effectors M-Ras
might signal through, we examined the ability of M-Ras(Q71L)
to interact with various known or putative Ras target proteins
in a yeast two-hybrid interaction assay. Ha-Ras bound strongly
to c-Raf-1, A-Raf, B-Raf, RalGDS, PI3K, and the Ras-binding
domains of Rin1 and AF6. However, while M-Ras interacted
with the Ras-binding domains of c-Raf-1 or AF6, it did not
significantly associate with full-length Raf proteins or the Ras
binding domains of various other Ha-Ras effectors (Table I).
This suggested that direct activation of Raf, PI3K, or Ral GEFs
might not be required for M-Ras-induced morphologic transfor-
mation. To determine whether M-Ras interacts with AF6 in
vivo, a FLAG-tagged full-length AF6 was co-expressed in 293T
human embryonic kidney cells with HA-tagged M-Ras(Q71L)
or Ha-Ras(G12V). Following immunoprecipitation of HA-
tagged Ras proteins, co-precipitated AF6 could be detected by
blotting with M2 anti-FLAG antibody (Fig. 8). M-Ras(Q71L)
was found to be more effective than Ha-Ras(G12V) in precipi-
tating AF6. Co-transfection of Ha-or M-Ras constructs with
pCMV2-FLAG-AF6 did not result in increased focus forming
activity (Fig. 7B),2 suggesting either that the endogenous AF6
FIG. 5. Ha- but not M-Ras can activate ERK2. A, NIH 3T3 cells
were transfected with 1 mg of empty pZIP or vector encoding Ha-
Ras(Q61L) or M-Ras(Q71L) along with 1 mg of pcDNA3 HA-ERK2.
Following serum starvation, cells were lysed, HA-ERK2 was immuno-
precipitated, and kinase activity was determined using myelin basic
protein as substrate. Data are representative of three experiments
performed in duplicate. B, a pooled population of G418-selected NIH
3T3 cells harboring pZIP or vector encoding M-Ras(Q71L) or Ha-
Ras(Q61L) were serum-starved, and cell lysates were blotted with anti-
activated ERK antibody. Data are representative of two independent
experiments. C, NIH 3T3 cells were transfected with pZIP plasmids as
in A, except they were cotransfected with pFLAG CMV-p38a. Following
serum starvation, p38 activity in cell lysates was determined using an
anti-activated p38 antibody. Anisomycin stimulation was for 10 min.
Data are representative of four independent experiments. MAPK, mi-
togen-activated protein kinase.
FIG. 6. Ha-Ras, M-Ras, and MEK induce Elk-1 activation. A,
NIH 3T3 cells were transfected with plasmids encoding the indicated
proteins, along with Gal4-Elk and 5XGal-Luc reporter plasmids. The
ability of Ras and MEK proteins to induce luciferase expression was
determined following serum starvation. Where indicated, Me2SO
(DMSO) vehicle (0.1%, v/v), 50 mM PD98059, or 10 mM SB203580 was
added 16–18 h prior to cell lysis. Results (mean 6 S.D.) are representative
of at least two experiments performed in duplicate. B, NIH 3T3 cells were
transfected with the indicated pZIP-ras plasmids. After 3 days, 50 mM
PD98059, 10 mM SB203580, or 0.1% Me2SO vehicle was added to the
growth medium. Fresh medium plus drug was added every 2 days, and
transforming foci were visualized after 14 days culture. Data are repre-
sentative of two experiments performed in triplicate. C, NIH 3T3 cells
were transfected with 1 mg of pMCL-MEKDED or 200 ng of pZIP
M-ras(Q71L), and transforming foci were visualized after 14 days of
culture. Data are representative of two experiments performed in
triplicate.
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is sufficient to support M-Ras induced transformation or that it
plays no role in this process.
M-Ras Is Activated by Sos1 and GRF1—It has previously
been demonstrated that residues within switch 1, switch 2, and
a-helix 3 of Ras contribute to its interaction with GEFs (5, 49).
Since M-Ras shares considerable sequence homology with Ha-,
Ki-, and N-Ras within these regions, we wished to determine if
M-Ras too was sensitive to Ras GEFs. Co-expression of wild
type M-Ras with the membrane-targeted catalytic domains of
Sos1 or GRF1 resulted in elevation of the M-Ras GTP/GDP
ratio (Fig. 9). Consistent with this result, Sos1 cooperated with
M-Ras to induce luciferase expression from a Gal/Elk luciferase
reporter plasmid, although GRF1 was less effective.2
M-Ras Is Regulated by the p120 Ras GAP—Residues within
switch 1 and the proximal region of switch 2 of Ha-Ras are
responsible for its interaction with p120 Ras GAP. These do-
mains are conserved between Ha- and M-Ras. To determine
whether M-Ras GTPase activity was sensitive to regulation by
p120 GAP, we expressed Ha-Ras and M-Ras as glutathione
S-transferase fusion proteins in E. coli and compared their
ability to hydrolyze bound [a-32P]GTP in the presence of the
purified GAP. As shown in Fig. 10, Ha- and M-Ras had similar
basal GTPase activities that were equally augmented by expo-
sure to p120 GAP. Therefore, it appears that M-Ras can be
regulated by some of the same GEFs and GAPs as Ha-Ras.
DISCUSSION
Ha-, Ki-, and N-Ras are expressed in a wide variety of tissues
and couple upstream stimuli from a diverse array of ligand-
activated receptors to multiple downstream effector proteins
(2, 5, 6). Recent data suggest that these prototypic Ras proteins
have different affinities for downstream targets and may elicit
different as well as common biological outcomes (50–55). Ras-
related proteins are typically activated by a limited repertoire
of upstream GEFs and interact with only select downstream
Ras effectors to provide an additional level of signaling speci-
ficity. For example, R-Ras and Rap1A respond differently to
Ras GEFs, activate some but not all Ras effectors, and have
significantly different biological effects to Ras, at least in part
due to association with unique downstream targets (13, 18, 23,
56–58). We report here the characterization of an additional
Ras family member, M-Ras. M-Ras shares slightly higher sim-
ilarity with TC21/R-Ras2 than other members of the Ras sub-
family of GTPases and so has also been referred to as R-Ras3
FIG. 7. M-Ras cooperates with Ras effectors to induce morpho-
logical transformation. A, NIH 3T3 cells were transfected with 20
ng/dish pZIP-M-ras(Q71L) along with 2 mg of plasmids expressing ac-
tivated Raf, Rac, Rho, or empty vector. Transforming foci were visual-
ized after 14 days culture. Representative of four experiments per-
formed in at least triplicate. B, NIH 3T3 cells were cotransfected with
plasmids encoding AF6 and/or M-Ras(Q71L) as indicated. Data are
representative of three experiments performed in triplicate.
TABLE I
M-Ras preferentially interacts with the Ras-binding domain of AF6
pBTM116-Ha-ras(G12V) or pBTM116-M-ras(Q71L) LexA DNA bind-
ing domain fusion constructs were expressed in yeast-containing plas-
mids encoding VP16 transactivation domain fusions of c-Raf-1, A-Raf,
B-Raf, PI3K p110d, and Ral GDS or the Ras-binding domains of c-Raf-1,
AF6, and Rin1 (42). The ability to induce b-galactosidase activity was
then determined using o-nitrophenyl b-D-galactopyranoside as sub-
strate. Data are representative of three experiments performed in du-
plicate on random colonies. Similar results were obtained using yeast
patches on nitrocellulose filters and correlated with the ability of yeast
to grow on His2 plates (11, strong growth; 1, partial growth; 2, no










AF6 11 292.9 11 417.9
c-Raf-1 N-term 11 15 1 5.1
c-Raf-1 1 5.7 2 1.3
A-Raf 11 8.9 2 1.1
B-Raf 11 23.6 2 1.1
PI3K 11 73.6 2 1.4
Ra1GDS 11 8.6 2 1.6
Rin1 11 9.6 2 1.6
FIG. 8. AF6 coimmunoprecipitates with Ha- and M-Ras. 293T
cells were transfected with empty vectors, HA-tagged Ha- or M-Ras, or
FLAG-tagged AF6 as indicated. Protein expression was confirmed by
immunoblotting cell lysates for Ras proteins using anti-HA antibody
(upper panel) or for AF6 using anti-FLAG antibody (middle panel). Ras
proteins were immunoprecipitated using anti-HA antibody, and copre-
cipitation of AF6 was determined by immunoblotting with M2 anti-
FLAG antibody (lower panel). As seen in lanes 2 and 3 (lower panel),
both Ha- and M-Ras could coimmunoprecipitate AF6. Data are repre-
sentative of four similar experiments.
FIG. 9. M-Ras is activated by Ras GEFs. 293T cells were trans-
fected with plasmids encoding epitope-tagged wild type M-Ras or Ha-
Ras along with pRCbac, pRCbac-(59-SosF) (34), pcDNA3, or pcDNA3
c-CDC25-CAAX (33) as indicated. After 36 h, the guanine nucleotide
pool was metabolically labeled in the absence of serum using 32Pi. Cells
were then lysed, and Ras-bound GTP and GDP were determined by
immunoprecipitation and thin layer chromatography. Sos1 and GRF1/
CDC25 elevated the GTP levels of both Ha-Ras and M-Ras. %GTP
indicates the average (GTP cpm/(1.5 3 GDP) cpm 1 GTP cpm) 3 100
ratio from two (Sos) or three (GRF) independent experiments.
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(29). Alignment of Ras-related proteins revealed that while the
switch I domain of M-Ras is completely conserved with that of
Ras and TC21, there is considerable divergence in the flanking
residues (28, 29) that could significantly influence the ability of
M-Ras to bind and/or activate Ras effectors.
The M-ras message level was reduced upon differentiation of
C2 myoblasts into myofibers (28). Since M-Ras overexpression
inhibited the differentiation of C2 myoblasts in the current
study, it is possible that its expression is linked to the suppres-
sion of muscle cell development. Studies on C3H10T1/2 cells
suggest that a novel Ras-activated signaling pathway is impor-
tant for the inhibition of myoblast differentiation (44, 59). Due
to its ability to inhibit myogenesis despite limited interaction
with Ha-Ras targets, M-Ras may provide a useful tool to iden-
tify this novel pathway.
Since Ras, TC21, and (less potently) R-Ras can induce mor-
phological transformation of cultured cells, we examined the
transforming potential of M-Ras harboring a strongly activat-
ing mutation. Although M-Ras was not as effective as Ha-Ras
in these assays, it had equivalent potency to R-Ras. A similar
observation has been made by Kimmelman et al. (29). Since
Ras is mutationally activated in ;30% of human tumors and
TC21 has also been found to be overexpressed or mutated in
several human tumor cell lines (10, 11, 60), it will be important
to establish whether M-Ras too can contribute to the develop-
ment of human malignancies.
It was proposed previously that the weaker transforming
ability of M-Ras versus Ha-Ras in NIH 3T3 focus forming
assays was due to its less effective activation of the Raf/ERK
cascade (29). This conclusion was based on the ability of M-Ras/
R-Ras3 to cooperate with Raf to induce ERK activation and
focus formation. Alternatively, the increase in Raf-induced
transformation may have been due to M-Ras-induced activa-
tion of a distinct, complementary pathway or pathways to
Raf/MEK/ERK. Indeed, it has been documented that Raf can
cooperate with other Ras effectors, including PI3K, RalGDS,
and the Rho family GTPases, Rho, Rac, and CDC42, to induce
transformation (48, 61–63). Consistent with this notion, we
have seen a significant effect of Rho, Rac, or Raf on M-Ras-
induced transformation. Since M-Ras could activate Elk-1, de-
spite its weak activation of ERK2, it was possible that it uti-
lized alternate pathways to Raf/MEK/ERK to elicit gene
expression. However, since MEK inhibitors almost completely
attenuated M-Ras-induced Elk-1 activation, gene expression is
presumably mediated by MEK. The ability of PD98059 to also
block M-Ras-induced focus formation suggested that MEK is a
key mediator of M-Ras-induced transformation. However, since
M-Ras was considerably more potent than the MEKDED mu-
tant (that strongly activated Elk-induced luciferase activity) at
inducing transformation (activated MEK is only transforming
in secondary focus assays (36, 64)), other downstream targets
must also contribute to M-Ras action. Although p38 has been
reported to activate Elk-1 in NIH 3T3 cells (65), we found that
the p38 inhibitor SB203580 potentiates M-Ras-induced trans-
activation. We are currently investigating the mechanism
whereby inhibition of p38 leads to increased basal and M-Ras-
induced Elk-1 activation.
Although TC21 and R-Ras associated with the isolated Ras-
binding domain of c-Raf-1, they did not interact with full-length
Raf (8, 56). A similar observation was made here with M-Ras
and is consistent with the inability of M-Ras to strongly acti-
vate ERKs or induce gene expression. It appeared that PI3Kd,
Rin, or RalGDS also may not contribute significantly to M-Ras-
induced transformation, based on their lack of interaction with
M-Ras(Q71L) in the two-hybrid assay. It must be noted, how-
ever, that there are multiple isoforms of these effectors that
might be differentially regulated by M-Ras (29). Indeed, we
have found that the PI3K inhibitor, LY2940022, can block
M-Ras-induced transformation.2
Two-hybrid protein interaction data indicated that the only
putative Ras effector tested that bound with significant affinity
to M-Ras was AF6. AF6 was originally identified as a chimeric
translocation partner of ALL-1 in certain human leukemias
(66). It has also been shown to interact with the C terminus of
Eph family receptor tyrosine kinases, via its PDZ motif (67),
and to the tight junction protein ZO-1. This latter interaction
may be responsible for the localization of AF6 to tight junctions
in epithelial cells and to sites of cell-cell contact in other cell
types (68, 69). Little is currently known about how AF6 might
mediate Ras function. However, some clues have come from
studies in Drosophila, where the AF6 homologue, Canoe, that
is involved in compound eye development, is genetically linked
to Ras. Further, since the Ras and ZO-1 binding sites on AF6
overlap, it has been proposed that Ras might compete with
ZO-1 to disrupt tight junction integrity (68). Consistent with
this notion, expression of activated Ras in MCF-10A breast
epithelial cells resulted in their acquiring a fibroblastic mor-
phology with a loss of adherens and tight junctions (70). Since
M-Ras could coprecipitate full-length AF6 from 293 cell lysates,
this interaction may be physiologically relevant and merits
further investigation. This is also the first demonstration of
Ha-Ras interaction with AF6 in vivo. Determination of whether
the higher affinity of AF6 for M-Ras(Q71L) versus Ha-
Ras(G12V) represents higher affinity toward M-Ras or lower
affinity for a G12V versus Q61L Ras mutant will require fur-
ther investigation. Regardless, the inability of AF6 to cooperate
with M-Ras to induce NIH 3T3 cell foci suggests that either the
endogenous AF6 is sufficient to support M-Ras induced trans-
formation or plays no role in this process.
Sequences within switch 1 and 2 are known to influence the
ability of p120 Ras GAP to activate the GTPase activity of Ras.
Since both switch domains of M-Ras are highly conserved with
those of Ha-Ras (the Y13–259 monoclonal antibody that recog-
nizes the secondary structure of Ras switch 2 can efficiently
immunoprecipitate M-Ras),2 it was not surprising that M-Ras
was sensitive to p120 GAP regulation. Several Ras-related
proteins, including the R-Ras family are sensitive to p120 Ras
GAP. Therefore, it is likely that divergent residues flanking
residues 32–40 of M-Ras are not critical for dictating GAP
FIG. 10. M-Ras GTPase activity is stimulated by p120 Ras GAP.
0.2 pmol of [a–32P]GTP-bound Ha- or M-Ras were incubated in the
absence (circles) or presence (squares) of recombinant p120 Ras GAP for
the indicated times. Hydrolysis of GTP was then determined following
separation of GTP and GDP by thin layer chromatography. Data are
representative of two experiments performed in duplicate. Open sym-
bols indicate Ha-Ras, and closed symbols indicate M-Ras.
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specificity. Since both Sos1 and GRF1 can activate M-Ras, it
appears that the extended effector-binding domain may not
contribute to GEF selectivity either. However, M-Ras did ap-
pear less responsive to GRF1 in luciferase assays.2 Regulation
by Sos1 suggests that M-Ras in addition to the prototypic Ha-,
Ki-, or N-Ras might mediate the growth-stimulatory signal ini-
tiated by receptor tyrosine kinases. Further, since M-Ras and
GRF1 are both abundantly expressed in brain, M-Ras may me-
diate signals associated with long term memory acquisition (71).
Ha-Ras T35S, E37G, and Y40C mutants that are defective in
their ability to activate Raf, PI3K, or RalGDS have been used
extensively over the past 3 years to establish a role for these
downstream effectors in Ras function (35, 63, 72, 73). One
outcome of these studies is the notion that additional Ras
effectors may exist. For example, Ramocki et al. reported that
although Ras(G12V/T35S), Ras(G12V/E37G), and Ras(G12V/
Y40C) can mimic the ability of Ras(G12V) to inhibit the differ-
entiation of C3H10T1/2 cells into a skeletal muscle lineage, this
effect cannot be mimicked by Rac and Rho nor blocked by the
MEK inhibitor PD98059 (44, 59). Since M-Ras does not interact
strongly with Raf, RalGDS, PI3K, or Rin and cooperates with
Rho to induce NIH 3T3 cell transformation, it will be important
to determine whether it induces its biological effects via targets
other than AF6 and, if so, whether these too contribute to
Ras-induced transformation. We are currently screening for
novel M-Ras targets that might mediate the biological effects of
it and other Ras family proteins.
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